Conference Proceedings
Whole blood FOLH1 mRNA expression and treatment response in metastatic castration-resistant prostate cancer (mCRPC).
Edmond Michael Kwan, Sarah Q To, Heidi C Fettke, Maria M Docanto, Patricia Bukczynska, Andrew Michael Mant, David William Pook, Nicole Ng, Lisa-Jane K Graham, Eva Segelov, Kate Mahon, Ian D Davis, Phillip Parente, Carmel Jo Pezaro, Lisa Horvath, Arun Azad
JOURNAL OF CLINICAL ONCOLOGY | AMER SOC CLINICAL ONCOLOGY | Published : 2019
Abstract
188 Background: Identifying predictive biomarkers for mCRPC patients receiving androgen receptor signalling inhibitors (ARSI) or chemotherapy remains an unmet clinical need. FOLH1 encodes for Prostate-Specific Membrane Antigen (PSMA), a type II glycoprotein highly expressed on prostate cancer cells. We designed a whole blood assay to detect FOLH1 mRNA, and correlated expression with clinical outcomes in patients commencing ARSI (abiraterone or enzalutamide) or chemotherapy (docetaxel or cabazitaxel). Methods: mCRPC patients commencing ARSI or chemotherapy were prospectively recruited at three Australian centres from June 2016 to July 2018. A quantitative reverse transcription polymerase cha..
View full abstract